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Drug resistance, an all too frequent characteristic of cancer, represents a serious barrier to successful treatment. Although many resistance
mechanisms have been described, those that involve membrane-resident proteins belonging to the ABC (ATP binding cassette) transporter
superfamily are of particular interest. In addition to cancer, the ABC transporter proteins are active in diseases such as malaria and leishmaniasis.
A recent renaissance in lipid metabolism, specifically ceramide and sphingolipids, has fueled research and provided insight into the role of
glycosphingolipids in multidrug resistance. This article reviews current knowledge on ceramide, glucosylceramide synthase and cerebrosides, and
the relationship of these lipids to cellular response to anticancer agents.
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The phenomenon of biocide and drug resistance arising in
biological systems is widespread. With surprising rapidity,
organisms evolve defenses to protect themselves from toxins
of all kinds. Increasingly, drug-resistant bacteria and viruses⁎ Corresponding author. Fax: +1 310 582 7325.
E-mail address: cabot@jwci.org (M.C. Cabot).
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doi:10.1016/j.bbamem.2006.08.012(for example, tuberculosis, Staphylococcus, HIV), pesticide-
resistant insects (lice, mosquitoes), and herbicide-resistant
weeds pose a serious and growing threat to human health and
the ecosystem. Although many resistance mechanisms have
been described, those that involve membrane proteins
belonging to the ABC transporter superfamily are best
understood. These proteins play a major role in such
devastating and widespread diseases as malaria, leishmaniasis,
and cancer, as they can impact drug disposition and modulate
drug interactions [1–6].
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Overexpression of the membrane efflux transporter P-
glycoprotein (P-gp), an ATP-binding cassette (ABC) transporter
protein, is one of the most consistent biological alterations in
drug resistance [1,7,8]. ABC proteins contain a hydrophobic
membrane-spanning domain with as many as six transmem-
brane helices and a hydrophobic cytosolic nucleotide-binding
domain [9]. P-gp (gene symbol ABCB1), a 170kDa protein,
was the first ABC protein demonstrated to confer resistance to
natural product agents used in the treatment of cancer [10,11].
In humans P-gp is encoded by the MDR1 gene [12]. A second
ABC protein, a 190-kDa membrane glycoprotein called MRP1
(multidrug resistance protein, gene symbol ABCC1), was
discovered shortly thereafter [13]. A more recently described
transporter is breast cancer resistance protein (BCRP, gene
symbol ABCG2), which must homodimerize to acquire
transport activity [14,15]. Although P-gp and related transpor-
ters all reduce the intracellular concentration of antitumor,
antiviral, and antibacterial agents via ATP-dependent effluxing,
these proteins have distinct properties. For example, MRP1 but
not MDR1 transports negatively charged natural product drugs
[16]. ABCG2/BCRP interacts with heme and other porphyrins
in a manner that exemplifies the tissue defense properties of the
efflux pumps [15], which are capable of transporting toxicants
(cationic, anionic, neutrally-charged), environmental carcino-
gens, metals, pesticides, and lipid peroxidation products. Of
particular interest are the lipid-transporting properties displayed
by some of the ABC proteins [17].
3. How ABC transporters impact response to drugs
Among the myriad effects of P-gp on drug disposition and
interaction is the restriction of intestinal absorption; a compara-
tive study found that plasma concentrations of HIV protease
inhibitors (indinavir, nelfinavir), which have poor absorption,
were 2 to 5 times greater in mdr1a (−/−) mice than in wild-type
mice [18]. Absolute bioavailability of the HIV drugs was 22% in
normal mice, as compared with 72% in the knockout mice.
Another murine study demonstrated that limited oral bioavail-
ability of paclitaxel was in part due to P-gp-mediated direct
excretion of drug from systemic circulation into the intestinal
lumen [19]. Grepafloxacin, an oral fluoroquinolone active
against S. pneumoniae and pneumococcal pneumonia [20], is a
substrate for two ABC transporters, MDR1 and MRP1 [21].
Bioavailability of fluoroquinolones is unfortunately limited by
P-gp-mediated biliary excretion [22]. CPT-11, an analog of
camptothecine, also exhibits extensive biliary excretion [23].
ABC transporter proteins also play a role in resistance of Plas-
modium falciparum to antimalarials [4], and resistance of
Leishmania to chemotherapy [5], a parasitic protozoan respon-
sible for some of the most devastating and prevalent diseases of
humans. The role of efflux in macrolide resistance (erythromy-
cin, clarithromycin, azithromycin) is clinically significant for
key pathogens such as S. pneumoniae, S. pyogenes, Haemo-
philus influenzae, and Escherichia coli [6]. Exaggerated drug
effluxing also poses barriers to successful treatment of cancer.Poor response to chemotherapy is usually due to drug
resistance [1,7]. Approximately 40% of cancer patients with
resectable disease and 80% of cancer patients with unresectable
disease have poor response to chemo- and radiotherapy. In
breast cancer alone, nearly 50% of patients demonstrate primary
and/or secondary resistance to doxorubicin [24]. The prevalence
of drug resistance in prostate and ovarian malignancies prevents
significant cure with current chemotherapeutic regimens. In
melanoma, which is characterized by high risk for early
metastasis, the commonly employed front-line anticancer
drugs do not improve prognosis [25]. In small cell lung cancer,
acquired resistance to multiple drugs is responsible for a
chemotherapeutic cure rate below 10% [26].
P-gp plays an important role in cancer chemotherapy [27]; it
is expressed in many types of untreated malignancies,
including breast, colon renal, and ovarian cancers, neuroblas-
toma, acute myeloid leukemia, non-Hodgkin's lymphoma, and
multiple myeloma [reviewed in Drug Resistance Updates 1,
190–200, 1998, [28]. Exposure to chemotherapy can also
upregulate P-gp expression, as occurs in acquired drug
resistance [29,30]. In breast cancer for example, a study by
Rudas et al. [31] revealed that expression of P-gp was 55%
before chemotherapy and 100% after chemotherapy. Breast
cancers treated by neoadjuvant therapy with fluorouracil,
doxorubicin, and cyclophosphamide responded with similar
enhancement [32].
4. Lipids in cancer
Among the richest of the vast amount of literature on lipids
and cancer, are the works of Fred Snyder, Robert Wykle, and
Ten-ching Lee and colleagues, specifically on ether-linked
lipids in neoplasms [33–35]. Reviews appear periodically on
the many aspects of lipids, the newest entries discussing
prostaglandins, non-steroidal anti-inflammatory drugs and
arachidonic acid metabolism in colorectal and other cancers
[36,37], and the effects of omega-3 fatty acids on cancer risks
[38]. Today's message suggests there is no significant
association between omega-3 fatty acids and cancer incidence.
Because of the varied types of glycosphingolipids that
compose cellular membranes and the trafficking and commu-
nication that occurs across these lipid (and protein) barriers,
glycolipid biology and chemistry has been of particular interest
in cancer research (see Fig. 1 for an abridged schematic of
ceramide metabolism). Lipids, including glucosylceramide,
lactosylceramide, and gangliosides, play an essential role in
cell development, cell death, tumor progression, and pathogen/
host interaction [39–41]. For example, radioresistant melanoma
cells rich in gangliosides, can be made radiosensitive by
exposure to either fumonisin B1, which blocks ganglioside
biosynthesis at the juncture of ceramide synthase, or Vibrio
cholerae neuraminidase, which cleaves cell surface ganglio-
sides. Conversely, adding bovine brain GM1 to radiosensitive
melanoma cells can confer radioresistance [42]. Studies have
also shown that tumor ganglioside metabolism plays a
significant role in modulating tumor formation and progression.
For instance, glucosylceramide synthase (GCS) inhibition using
Fig. 1. Ceramide metabolism pathway.
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murine melanoma model, produced a delay in tumor develop-
ment [43]. Similar imino sugars that inhibit GCS, such as
OGT2378, limit glycosphingolipid synthesis in melanoma cells
without antiproliferative or cytotoxic effects in vitro, but do
show marked inhibition of melanoma growth in vivo [44].
Studies with tumor gangliosides have demonstrated their
potential as markers. In melanoma patients, serum total
ganglioside levels correlate with clinical course post-therapy
[45], and in organ-confined versus metastatic androgen-
receptor-negative prostate cancer, ganglioside patterns may
provide keys to vaccine design [46].
Glycosphingolipid composition studies in MCF-7 and
MDA-MB-231 breast cancer cells showed that ganglioside
content was 4-fold higher in the more aggressive, hormone-
independent MDA-MB-231 cell line. In particular, GM3 levels
were 18-fold higher in MDA-MB-231 cells. This may have
important implications, because GM3 is thought to be involved
in regulation of growth factor function [47]. In Lewis lung
carcinoma cells, treatment with D-threo-1-phenyl-2-decanoyla-
mino-3-morpholino-1-propanol (D-PDMP), a GCS inhibitor
that limits glycosphingolipid production, reduced the lung-
colonizing capacity of cells in inoculated mice by 70%. After
removal of PDMP, cancer cell capacity to metastasize was
completely restored [48]. Another study involving cerebrosides
demonstrated that lactosylceramide supplements to human
fibroblasts modified integrin function by modulating integrin
clustering in microdomains and by regulating integrin endocy-
tosis via caveolae [49]. This suggests that aberrant levels of
glycosphingolipids found in cancer cells influence cell
attachment events by direct effects on integrin clustering and
internalization [49]. Our studies have shown that addition of
glucosylceramide (short-chain analog) to the medium of
cultured epidermoid carcinoma cells, enhanced MDR1 gene
expression [50].
Studies in animal models have also demonstrated a
connection between glycolipids and tumor development. For
example, melanoma cells depleted of endogenous gangliosidesby treatment with 1-phenyl-2-hexadecanoylamino-3-pyrroli-
dino-3-propanol (PPPP) show poor tumorigenic capacity
when injected into mice [51]. After 4weeks, only 40% of the
mice developed tumors compared with 100% of mice injected
with mock-PPPP treated melanoma cells [51]. Another study in
melanoma employed antisense transfection to target GCS [52];
in this genetic approach, by regulating glycosphingolipid
synthesis, only 2% of mice injected with antisense-transfected
melanoma cells formed tumors, compared to approximately
50% of mice in control groups [52].
5. Glycosphingolipids in drug-resistant cancer cells
A comprehensive review by Pallarés-Trujillo et al. [53]
discusses the role of cholesterol, phospholipids, and phospho-
lipases on drug influx and the effect of lipid composition on P-
gp transport. Until the mid-1990s, relatively few works have
been directed at studies of glycolipids in drug resistance.
Some of the first studies demonstrated that drug-resistant
cancer cell lines accumulate glucosylceramide [54,55]. For
example, multidrug-resistant MCF-7-AdrR breast cancer and
KB-V-1 epidermoid carcinoma cells contain higher levels of
glucosylceramide than their drug-sensitive counterparts, MCF-
7 and KB-3-1 [55,56]. The doxorubicin-resistant human
ovarian carcinoma cell line, A2780AD, has 3-fold higher
level of glucosylceramide and galactosylceramide compared to
wild-type A2780 cells [57]. Also, the fenretinide-resistant
A2780 cell line has been characterized by a 6-fold higher
expression of ganglioside levels, notably GM3 and GM2,
when compared to fenretinide-sensitive wild-type cells [58].
NIH:OVCAR-3, a human ovarian adenocarcinoma cell line
established from a patient resistant to doxorubicin, melphalan,
and cisplatin, also expresses high levels of glucosylceramide
[55]. Moreover, analysis of tumors from selected cancer
patients who failed to respond to chemotherapy treatment
demonstrated elevated glucosylceramide levels [55]. These
studies point to the utility of glucosylceramide as a marker of
multidrug resistance.
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Studies have demonstrated that drug sensitivities can be
altered by manipulating cellular glycosphingolipid metabolism.
For example, transfecting wild-type MCF-7 cells with GCS
confers resistance to doxorubicin [39]. The same transfection
potentiated resistance to tumor necrosis factor alpha (TNFα)
[59], a tumor-killing cytokine that regulates apoptosis via
ceramide generation from sphingomyelin [60]. The reverse
scenario has been demonstrated by transfecting MCF-7-AdrR
(multidrug resistant) cells with GCS antisense, a maneuver that
conferred sensitivity of the cells to anthracyclines, Vinca
alkaloids, and taxanes [61,62]. Antisense GCS transfection
can also decrease the growth rate of neuroepithelioma cells and
limit tumorigenicity in melanoma [52,63]. Recently, antisense
oligodeoxyribonucleotides to GCS have been used to enhance
doxorubicin sensitivity in multidrug-resistant breast and ovarian
cancer cells [64], and similar results have been demonstrated
through use of the “P-drug” inhibitors of GCS, such as 1-
phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP).
P-drugs are structural analogs of glucosylceramide, the natural
GCS substrate [65]. MCF-7-AdrR cells exposed to PPMP
become sensitive to anticancer agents [50]. In neuroblastoma
cells, D,L-threo-PDMP increases sensitivity to paclitaxel and
vincristine [66]. Other studies have shown that combining D,L-
threo-PPPP, a chemical cousin of PPMP, with vincristine
increases apoptosis levels in CCRF-CEM leukemia cells over
vincristine alone [67]. A study by Nicholson et al. [68] also
demonstrated that PPMP and PPPP preferentially kill drug-
resistant variants of KB-3-1 cells. These studies suggest that
limiting the synthesis of glycolipids could be one approach to
dampening drug resistance. Along these lines, MCF-7-AdrR
cells transfected with a GCS-specific small interfering RNA
(siRNA) demonstrated reduced GCS expression and enhanced
chemosensitivity [69].
Enthusiasm in the area of glycosphingolipids and chemo-
therapy was generated by a landmark study in leukemia wherein
it was shown that daunorubicin, tumor necrosis factor-alpha,
Fas, and ionizing radiation stimulated ceramide generation and
elicited apoptosis [70]. Subsequent works led to the notion that
targeting enzymes of ceramide clearance might allow for
increases in endogenous levels of ceramide, leading to
improved cytotoxic responses to chemotherapy in tumor cells.
In a study by Selzner et al. [71], ceramide analogs were
employed to block ceramidase in metastatic human colorectal
cancer, causing cell death that was facilitated by increases in
intratumoral ceramide content with activation of apoptotic
cascades. Similarly, in a nude mouse model, this approach
completely prevented colorectal tumor growth. A study in
prostate cancer has also demonstrated the utility of inhibiting
ceramidase to increase ceramide levels in vitro and in vivo [72].
Work by Lavie et al. [73] demonstrated that agents commonly
employed to block P-glycoprotein such as tamoxifen, cyclo-
sporine A, and verapamil, also retarded ceramide clearance by
inhibiting ceramide glycosylation. For example, triphenylethy-
lene antiestrogens, such as tamoxifen, blocked conversion of
ceramide to glucosylceramide [73,74], thereby promotingincrease in cellular ceramide. Although increases in ceramide
with tamoxifen alone were moderate, combining tamoxifen
with agents such as doxorubicin [75] or the cyclosporin A
analog, SDZ PSC 833 (Valspodar), increased ceramide levels by
as much as 11-fold, and had marked antiproliferative impact
[76].
Other works have demonstrated the therapeutic benefits of
manipulating glycosphingolipid metabolism. For instance, in
colorectal cancer cells, when glucosylceramide production is
blocked by PPMP, irinotecan-induced cell death increases by
88%, compared to irinotecan alone [77]. In neuroblastoma,
PDMP treatment can increase sensitivity to paclitaxel and
vincristine [66]. In another study in neuroblastoma cells,
fenretinide exposure induced ceramide generation, enhanced
glucosylceramide synthase activity, and promoted GD3 accu-
mulation through increased GD3 synthase activity; these effects
associated with the production of reactive oxygen species
(ROS) and apoptosis [78]. The authors concluded that
fenretinide-mediated apoptosis was orchestrated by sphingo-
myelinase, GCS, and GD3 synthase.
Although many studies demonstrate the importance of GCS
in regulating chemosensitivity, work with GCS inhibitors such
as the imido sugar derivative N-nonyl-deoxygalactonojiri-
mycin, at millimolar concentrations [79], and studies conducted
with specific cancer cell types, such as GM95 mouse melanoma
[80], do not support the idea of targeting GCS to enhance
chemotherapy response. Nevertheless, miglustat, an imido
sugar that reversibly inhibits GCS, is indicated for treatment
of patients with type 1 Gaucher disease, although its use is
associated with significant side effects [81]. It is clear that
altering GCS activity, either chemically or genetically, has been
helpful in illustrating the impact of ceramide metabolism on
cellular response to anticancer drugs, with some studies
showing selectivity in cancer versus normal cells. For example,
PDMP treatment has been shown to sensitize MCF-7-AdrR and
P-gp-overexpressing MDA-MB-435 cells to paclitaxel and
vincristine but not alter the chemosensitivity of the wild-type
cell lines [82]. Other work on GCS and chemotherapy responses
has shown that the cytotoxicity of 4-HPR, N-(4-hydroxyphenyl)
retinamide or fenretinide, a potent ceramide generator [78,83],
could be enhanced in ten different tumor cell lines by the
addition of PPMP and other modulators of ceramide metabo-
lism [84]. A recent study by Sun et al. [85] demonstrates that
GCS knockdown by RNA interference reverses multidrug
resistance in human breast cancer cells. In a study of radiation
resistance, a combination of three inhibitors of sphingolipid
metabolism elevated ceramide levels and reversed resistance to
radiation in squamous cell carcinoma [86]. This suggests that
manipulation of ceramide metabolism may offer new opportu-
nities for overcoming radioresistance in cancer, a subject that
has been recently reviewed [87].
7. P-glycoprotein and glycosphingolipids
P-gp can function as a broad-specificity outwardly-directed
flippase for simple glycosphingolipids and membrane phos-
pholipids [88,89]. Interestingly, overexpression of GCS and
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melanoma, colon cancer, and epidermoid carcinoma (head/
neck) cells [90]. This relationship was shown clearly in the
head/neck carcinoma cell line KB-3-1 and its vinblastine-
resistant sublines KB-V.01, KB-V.1, and KB-V1, listed in order
of increasing multidrug resistance. In this model, GC, GCS
mRNA, GCS protein, and P-gp increased with increased
vinblastine selection pressure. Thus, selection pressure for
natural product drug resistance not only upregulates MDR1
[1,29,30], but enhances ceramide metabolism through GCS.
Kok et al. [91,92] have reported similar findings in HT29 colon
cancer cells selected for colchicine resistance. In their study,
increases in glucosylceramide levels occurred concomitantly
with upregulation of MRP1 expression, showing that the two
are tightly connected. Although the levels of glucosylceramide
were higher, GCS expression and activity were not upregulated
in the colchicine-resistant model. Our group recently showed
that GCS inhibition via either GCS antisense, PPMP treatment,
or GCS siRNA, downregulated the expression of MDR1 in
multidrug resistant cancer cells [50]. For example, treatment of
multidrug-resistant epidermoid carcinoma cells with PPMP
induced an 84% decrease in MDR1 mRNA levels, with a P-gp
protein level drop of 50%, compared with untreated control
[50]. In a human ovarian cancer cell model, sphingomyelin,
galactosylceramide, and glucosylceramide levels were signifi-
cantly elevated in P-gp-overexpressing cells compared to wild-
type cells [57]. In hepatoma it was shown that lactosylceramide
was elevated in the MDR1-overexpressing cell line, a result of
transcriptional upregulation of the enzyme, lactosylceramide
synthase [93]. Other support for a link between glycolipids and
multidrug resistance can be found in work showing that PPMP
exposure modulates the expression of MDR1 (mRNA) in
doxorubicin-resistant human ovarian cancer cells [94]. Further,
in multidrug-resistant, P-gp-expressing epidermoid carcinoma
cells, high GCS expression was shown to be linked to resistance
[83]. A recent study in cholesterol metabolism showed that
depletion of membrane cholesterol altered P-gp localization and
abolished efflux [95]. These works suggest that lipids play an
important role in the expression and function of the multidrugFig. 2. Influence of C8-ceramide exposure on morphology and P-glycoprotein exp
passages in culture medium (RPMI-1640, 10% FBS) containing C8-ceramide (5.0μg
supplemented MDA-MB-231/C8 (400×). (B) Western blot using C219 monoclonal
MDA-MB-231/C8 cells. MCF-7-AdrR (doxorubicin-resistant MCF-7 cells) were use
denotes molecular weight markers.resistant phenotype [50]. Another study, however, demonstrates
that decreasing the levels of ceramide in leukemia cells, by
activation of GCS and sphingomyelin synthase, promoted
chemoresistance through Bcl-2 and not MDR1 expression [96].
Several studies have entertained the notion that the P-drugs
interact with P-gp, similar to pump antagonists such as
verapamil or cyclosporine A. In hepatoma cells, PDMP has
been shown to moderately inhibit P-gp activity and potentiate
apoptosis that is induced by doxorubicin exposure [97]. In
neuroblastoma, PDMP treatment decreases efflux of paclitaxel
and vincristine, similar to the P-gp antagonist, SDZ PSC 833,
suggesting an effect of PDMP on P-gp function [66]. A study in
drug-resistant leukemia cells showed P-gp function was
stimulated by gangliosides, whereas glucosylceramide, lacto-
sylceramide, and ceramide had no effect [98]. In that study,
gangliosides were thought to be important P-gp regulators,
perhaps through their capacity to modulate P-gp phosphoryla-
tion. In studies of sphingolipid composition in human
neuroblastoma, cells with high MDR1 and MRP1 expression
and functional activity contained higher sphingolipid levels
compared to neuroblastoma cell lines with poor ABC
transporter activity [99]. Another study showed that P-gp-
positive cell lines (KG1a, TF-1) were resistant to apoptosis
induced by C8-ceramide, compared to P-gp-negative cell lines
(HL-60, U937) [100]. The same study showed that glucosylcer-
amide inhibited P-gp activity in TF-1 cells, and that P-gp
inhibition by cyclosporin A and GF120918 decreased GCS
activity, lactosylceramide formation, and rhodamine 123
accumulation in the Golgi of TF-1 cells. These results indicate
that the influence of P-gp on glucosylceramide metabolism
contributes to the resistance of P-gp-positive TF-1 cells to
ceramide-induced apoptosis [100].
8. Conclusions—lipids and the MDR1 phenotype
Glycosphingolipids impact cellular sensitivity to anticancer
agents, in particular the natural product, ceramide-generating
chemotherapy drugs. It is also well accepted that ceramide
drives cell death signaling elicited in response to exposure toression in MDA-MB-231 human breast cancer cells. Cells were grown for 12
/ml). (A) Photomicrograph of wild-type MDA-MB-231 (400×) and C8-ceramide
antibody to P-gp. 100μg total cell protein was loaded for MDA-MB-231 and
d as + control (positive control), and 0.25μg total cell protein was loaded. m.w.
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been shown to stimulate monocytic differentiation in human
promyelocytic leukemia [101]. The notion, however, of
ceramide and glycolipids imparting drug resistance has not
been explored. In an attempt to answer this question, we
exposed wild-type, P-gp-negative MDA-MB-231 breast cancer
cells to low dose C8-ceramide for extended passages. Cells
(passage 12) were then evaluated and compared to the
ceramide-naïve MDA-MB-231 counterpart. Fig. 2A (photomi-
crograph) shows that the C8-ceramide-grown cells (MDA-MB-
231/C8) were rounder, larger, and tended to grow in islands
consisting of clumped, multilayered cells, compared to wild-
type MDA-MB-231 cells. In addition, MDA-MB-231/C8 cells
had significantly higher levels of MDR1 mRNA (45-fold)
compared to MDA-MB-231 cells. Fig. 2B shows P-gp
expression as determined by Western blot. Compared to
MDA-MB-231 cells in which P-gp was undetectable under
these conditions, MDA-MB-231/C8 cells expressed relatively
high levels of P-gp. These findings indicate that lipids elicit
expression of the multidrug-resistant phenotype in human
cancer cells. Ceramide's role as a messenger of cytotoxic
response to chemotherapy may be linked to the multidrug
resistance pathway.
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